BFRI חוב כולל להון Biofrontera

This price visualization, which assists in the basic asset valuation, demonstrates that the debt-to-equity ratio for Biofrontera Inc. (BFRI) is 1.31, while ointment logistics have been fully outsourced to third-party operators to reduce costs. Biofrontera Inc. (BFRI) generates revenue through the supply of photodynamic systems and Ameluz to US medical centers. The company's personnel policy relies on an aggressive bonus system for sales representatives driven by strict KPIs.

This ratio compares total liabilities to equity, determining the business's degree of dependence on debt financing and its overall financial stability. By analyzing the total debt-to-equity ratio, an investor can assess the ability of Biofrontera Inc. (BFRI) to scale sales of dermatological products, leveraging high gross margins to optimize operating leverage without excessive debt pressure.